NanoViricides (NYSEAMERICAN:NNVC) Share Price Crosses Above Fifty Day Moving Average of $0.00

NanoViricides, Inc. (NYSEAMERICAN:NNVCGet Rating)’s stock price passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $0.00 and traded as high as $1.67. NanoViricides shares last traded at $1.65, with a volume of 8,228 shares changing hands.

NanoViricides Stock Up 4.4 %

The firm has a market cap of $19.16 million, a P/E ratio of -2.01 and a beta of 0.58.

NanoViricides (NYSEAMERICAN:NNVCGet Rating) last issued its quarterly earnings results on Thursday, October 13th. The company reported ($0.15) EPS for the quarter.

Institutional Trading of NanoViricides

Several institutional investors and hedge funds have recently bought and sold shares of the stock. UBS Group AG raised its stake in NanoViricides by 114.5% in the first quarter. UBS Group AG now owns 17,448 shares of the company’s stock valued at $37,000 after buying an additional 9,314 shares during the period. Two Sigma Investments LP bought a new stake in NanoViricides in the third quarter valued at approximately $59,000. Renaissance Technologies LLC raised its stake in NanoViricides by 18.4% in the third quarter. Renaissance Technologies LLC now owns 71,066 shares of the company’s stock valued at $123,000 after buying an additional 11,066 shares during the period. Finally, Vanguard Group Inc. raised its stake in NanoViricides by 7.1% in the third quarter. Vanguard Group Inc. now owns 458,072 shares of the company’s stock valued at $792,000 after buying an additional 30,194 shares during the period. Institutional investors own 8.29% of the company’s stock.

About NanoViricides

(Get Rating)

NanoViricides, Inc, a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Monkeypox Treatment for Monkeypox virus; Adenovirus 71 Treatment for severe pediatric hepatitis caused by Adenovirus 71 or related viruses; and HerpeCide Program Expansion Drug project that develops broad-spectrum nanoviricide drugs against different herpes viruses for different indications.

See Also

Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.